Amgen (AMGN) Announces KYPROLIS Phase 3 CLARION Trial Missed Primary Endpoint Sep 27, 2016 05:52AM
Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients Sep 27, 2016 04:00AM
Amgen Opens Nomination Process For LabCentral Residency Sep 26, 2016 05:00PM
Amgen (AMGN), UCB Announce FDA Acceptance of BLA For Romosozumab Sep 26, 2016 04:01PM
Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab Sep 26, 2016 04:00PM
View Older Stories

Sep 26, 2016 06:23AM Amgen's (AMGN) AMJEVITA Approved by U.S. FDA
Sep 23, 2016 06:04PM FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases
Sep 20, 2016 09:11AM Amgen (AMGN) Announces Repatha Phase 3 GLAGOV Trial Met Primary, Secondary Endpoints
Sep 20, 2016 09:00AM Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)
Sep 19, 2016 06:38AM Amgen (AMGN), UCB Announce Significant Data from Romosozumab Phase 3 in Osteoporosis
Sep 18, 2016 11:00AM Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
Sep 16, 2016 07:36AM Amgen (AMGN) Affirms Receipt of Positive CHMP Opinion on Parsabiv for Secondary Hyperparathyroidism
Sep 16, 2016 07:34AM Amgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis
Sep 15, 2016 04:33PM Amgen (AMGN) Says Phase 2 on Erenumab Shows Statistically Significant Reduction in Migraines
Sep 15, 2016 04:30PM Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine
Sep 14, 2016 04:00PM Amgen To Webcast Investor Call
Sep 13, 2016 04:00PM Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Sep 8, 2016 04:00PM Amgen To Present At The Morgan Stanley Global Healthcare Conference
Sep 8, 2016 04:00PM Amgen To Present At The Morgan Stanley Global Healthcare Conference
Sep 7, 2016 04:06PM Amgen (AMGN) to Highlight 19 Abstracts at ASBMR Meeting
Sep 7, 2016 04:00PM Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting
Sep 7, 2016 04:00PM Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting
Sep 1, 2016 04:01PM Amgen (AMGN) Receives FDA Approval for BLINCYTO sBLA in Ph- r/r ALL
Sep 1, 2016 04:00PM FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Sep 1, 2016 04:00PM FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Sep 1, 2016 09:01AM Amgen (AMGN) Acquires Global AMG 420 Rights from Boehringer Ingelheim
Sep 1, 2016 09:00AM Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma
Sep 1, 2016 09:00AM Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma
Sep 1, 2016 08:38AM Amgen (AMGN) Announces Servier Exercises Option to Commercialize Omecamtiv Mecarbil in Europe
Sep 1, 2016 08:30AM Amgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure
Sep 1, 2016 08:30AM Amgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure
Aug 29, 2016 09:03AM Amgen (AMGN) Announces Prolia Phase 3 Met Primary, Secondary Endpoints in Glucocorticoid Therapy Patients
Aug 29, 2016 09:00AM Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy
Aug 29, 2016 09:00AM Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy
Aug 29, 2016 02:00AM New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016
Aug 29, 2016 02:00AM New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016
Aug 24, 2016 06:06PM Amgen (AMGN) Receives CRL from FDA on Parsabiv NDA
Aug 24, 2016 06:03PM Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
Aug 22, 2016 09:02AM Amgen (AMGN) to Present 11 Abstracts at ESC, Including Data Evaluating Repatha
Aug 22, 2016 09:00AM New Data Add To Understanding Of Repatha® (Evolocumab) In Multiple Patient Populations
Aug 2, 2016 08:02AM Amgen (AMGN), Advaxis (ADXS) Enter ADXS-NEO Global Development, Commercialization Agreement
Aug 2, 2016 08:00AM Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
Jul 27, 2016 04:01PM Amgen Reports Second Quarter 2016 Financial Results
Jul 22, 2016 04:30PM Amgen Announces Webcast Of 2016 Second Quarter Financial Results
Jul 22, 2016 04:00PM Amgen Announces 2016 Third Quarter Dividend
Jul 22, 2016 06:09AM Amgen (AMGN), UCB Submit Romosozumab BLA to U.S. FDA as Osteoporosis Treatment
Jul 22, 2016 01:00AM Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA
Jul 21, 2016 09:04AM Amgen (AMGN), Allergan (AGN) Announce Results from ABP 980 Phase 3 in HER2+ Breast Cancer; Superiority Not Ruled Out
Jul 21, 2016 09:00AM Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Jul 20, 2016 08:29PM Amgen Announces Settlement Of Securities Litigation
Jul 14, 2016 06:06AM Amgen (AMGN), Daiichi Sankyo Enter Biosimilars Commercialization Agreement in Japan
Jul 13, 2016 09:00PM Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Jul 12, 2016 07:32AM Amgen (AMGN) Announces Meeting with U.S. FDA to Discuss ABP 501 BLA
Jul 12, 2016 07:30AM Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab
Jul 11, 2016 09:03AM Amgen's (AMGN) Repatha Pushtronex System Receives FDA Approval
View Older Stories